Regen BioPharma Inc (RGBPP) Financiero

Regen Biopharma, Inc. is a biotechnology company, which engages in the business of developing regenerative medical applications and advancing novel technologies through pre-clinical and Phase I and II clinical trials. The company is headquartered in La Mesa, California. The company went IPO on 2014-09-03. The firm is focused on developing treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space. The firm is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. Its primary program consists of identifying small molecules that inhibit or express NR2F6 to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The firm is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).